External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers
Laminopathy is a relatively rare but increasingly recognized genetic disease (due to a mutation in LMNA gene encoding lamin A/C proteins) associated with a poor prognosis related to malignant ventricular arrhythmias (MVA) and progression to end-stage heart failure. Twenty-four patients were part of the previous work that identified the four risk factors 6 and were excluded from the current analysis. The external independent validation cohort consisted therefore of 77 patients. We recorded for all patients the four previously identified predictive factors (NSVT, LVEF < 45%, male sex, and non-missense mutations) and MVA during follow-up, defined as appropriate ICD treatment, cardiopulmonary resuscitation, or sudden cardiac death. We validated the model on two sub-cohorts: the first sub-cohort consisted of 77 patients, the second sub-cohort consisted of 64 relatives. We divided each cohort according to the presence of risk factors (0, 1, ≥ 2 risk factors) and compared groups by the log-rank test. We then assessed the performance of the Cox model derived from the first cohort depending on the presence of risk factors.
In the cohort of 77 LMNA mutation carriers, median age was 43 years, 46% were men, 13 (16%) had LVEF < 45%, 24 (31%) carried non-missense mutation, 24 (31%) had NSVT, 11 had an ICD at baseline and 23 ICDs have been implanted during the follow-up. Over a median follow-up of 3.4 years, 16 patients (20%) experienced MVA ( Figure 1A) . The rate of MVA-free survival at 3 years was 100% in patients with no risk factors (n = 18), 84% in patients with one risk factor (n = 31), and 75% in patients with ≥ 2 risk factors (n = 28) (P < 0. ...................................................................................................................................................................................................................................   ...................................................................................................................................................................................................................................... 
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In the sub-cohort of 64 relatives, median age was 39 years, 39% were men, 6 (9%) had LVEF < 45%, 19 (29%) carried a non-missense mutation, and 14 (22%) had NSVT. Over a median follow-up of 4.8 years, only five patients (8%) experienced MVA. Occurrence of MVA was significantly related to the presence of risk factors ( Figure 1B) (P = 0.04).
Prognostic models, most of which are multivariable, should not enter clinical practice unless external validation has confirmed their effective performance. In the present study, we were able to validate the predictive role of the four risk factors for prediction of MVA in an independent population of 77 patients. These risk factors were also validated in a sub-cohort of relatives, although of less statistical significance, probably related to the lower incidence of arrhythmic events.
Interestingly, we observed that no mutation carriers experienced any ventricular arrhythmic event in the absence of any risk factor, suggesting that a low-risk group can be identified. Conversely, we observed that patients with at least two risk factors experienced frequent MVA, supporting ICD prophylactic implantation in these patients. Further studies on larger populations are needed to refine the precise threshold for ICD implantation in primary prevention and to identify additional risk tools, such as magnetic resonance imaging or strain echocardiography, that could improve the prediction of sudden cardiac death in LMNA mutation carriers.
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